Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 10/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | EPX | P11678 | 1/20 | 0.40 |
| ▸ | LPO | P22079 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028774 | 0.86 | DYRK1A (0.44) | LTA4HCDK8CSF1RPDGFRBPDGFRA | |
| SCHEMBL23900811 | 0.83 | LOXL2 (0.49) | LTA4HCDK8MPOTPOEPX | |
| SCHEMBL23900459 | 0.81 | CDK8 (0.50) | LTA4HCDK8CSF1RFLT3PDGFRB | |
| SCHEMBL16028640 | 0.81 | CSF1R (0.56) | TGFBR1CSF1RFLT3PDGFRBPDGFRA | |
| SCHEMBL16028930 | 0.81 | GRM5 (0.47) | LTA4HCDK8PIK3CAMTOR | |
| SCHEMBL23888645 | 0.81 | MPO (0.43) | LTA4HCDK8FYNMPOTPO | |
| SCHEMBL30086973 | 0.81 | MPO (0.43) | LTA4HCDK8FYNMPOTPO | |
| SCHEMBL23900460 | 0.81 | ASIC3 (0.50) | LTA4HCDK8FYNMPOTPO | |
| SCHEMBL28341054 | 0.81 | MPO (0.39) | LTA4HCDK8CSF1RFYNMPO | |
| SCHEMBL16029265 | 0.80 | LTA4H (0.40) | LTA4HCDK8CSF1RPDGFRAFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2968287-B1 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382228-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2968287-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | LTA4H 2824/4885CDK8 147/4885TGFBR1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.